Capricor Therapeutics, Inc. ( CAPR ) shares are trading higher Tuesday after the company reported completion of next steps regarding CAP-1002, a potential treatment option for Duchenne Muscular Dystrophy (DMD).

The Details: The FDA agreed to a pre-Biologics License Application meeting based on data from two clinical studies, HOPE 2 and HOPE 3. The company can begin its BLA filing with a rolling submission, meaning pre-agreed upon parts can be submitted as they are completed. The rolling submission is planned to begin in the 2024 third quarter.

Dr. Linda Marbán, Capricor’s CEO stated, “Furthermore, we are looking forward to our presentation of additional 3-year data from our HOPE-2 OLE study at the upcoming PPMD [Parent Project Muscular Dystrophy] conference which we believe will add further evidence of the efficacy and safety of CAP-1002.”

How To Buy Capricor Therapeutics Stock

Besides going to a brokerage platform to purchase a share – or fractional share – of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument.

For example, in Capricor Therapeutics ( CAPR ) 's case, it is in the Health Care sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.

See Also: Why Calavo Growers Shares Are Trading Higher By 12%; Here Are 20 Stocks Moving Premarket

CAPR Price Action: At the time of publication, Capricor Therapeutics ( CAPR ) stock is trading 3.23% higher at $5.58 according to data from Benzinga Pro.

Image: Michal Jarmoluk from Pixabay